Last reviewed · How we verify

Empyema of pleura — Treatment Landscape & Competitive Intelligence

Empyema of pleura (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Empyema of pleura, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cleocin T CLINDAMYCIN PHOSPHATE Pfizer Lincosamide Antibacterial 1972-01-01
Cleocin clindamycin Generic (originally Upjohn/Pfizer) Lincosamide antibiotic 50S ribosomal protein L10 1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Empyema of pleura
  2. Generic (originally Upjohn/Pfizer) · 1 drug in Empyema of pleura
  3. Pfizer · 1 drug in Empyema of pleura

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Empyema of pleura:

Cite this brief

Drug Landscape (2026). Empyema of pleura — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/empyema-of-pleura. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing